A careful reassessment of anthracycline use in curable breast cancer

Abstract It has been over three decades since anthracyclines took their place as the standard chemotherapy backbone for breast cancer in the curative setting. Though the efficacy of anthracycline chemotherapy is not debatable, potentially life-threatening and long-term risks accompany this class of...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Sara Alsterlind Hurvitz, Nicholas P. McAndrew, Aditya Bardia, Michael F. Press, Mark Pegram, John P. Crown, Peter A. Fasching, Bent Ejlertsen, Eric H. Yang, John A. Glaspy, Dennis J. Slamon
Format: article
Langue:EN
Publié: Nature Portfolio 2021
Sujets:
Accès en ligne:https://doaj.org/article/aad7894979b94db08a790483d6338a18
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!